Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 2:7:1.
doi: 10.1186/1471-2407-7-1.

Improving the quality and efficiency of follow-up after curative treatment for breast cancer--rationale and study design of the MaCare trial

Affiliations

Improving the quality and efficiency of follow-up after curative treatment for breast cancer--rationale and study design of the MaCare trial

Merel L Kimman et al. BMC Cancer. .

Abstract

Background: After curative treatment for breast cancer women frequently attend scheduled follow-up examinations. Usually the follow-up is most frequent in the first 2-3 years (2-4 times a year); thereafter the frequency is reduced to once a year in most countries. Its main aim is to detect local disease recurrence, or a second primary breast cancer, but also to provide information and psychosocial support. However, the cost-effectiveness of these frequent visits is under much debate, leading to a search for less intensive and more cost-effective follow-up strategies. In this paper the design of the MaCare trial is described. This trial compares the cost-effectiveness of four follow-up strategies for curatively treated breast cancer patients. We investigate the costs and effects of nurse-led telephone follow-up and a short educational group programme.

Methods/design: The MaCare trial is a multi centre randomised clinical trial in which 320 breast cancer patients are randomised into four follow-up strategies, focussed on the first 18 months after treatment: 1) standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the educational group programme; 4) arm 2 with the educational group programme. Data is collected at baseline and 3, 6, 12 and 18 months after treatment. The primary endpoint of the trial is cancer-specific quality of life as measured by the global health/QoL scale of the EORTC QLQ-C30. Secondary outcomes are perceived feelings of control, anxiety, patients' satisfaction with follow-up and costs. A cost-effectiveness analysis will be performed from a societal perspective.

Discussion: Reduced follow-up strategies for breast cancer have not yet been widely applied in clinical practice. Improvement of psychosocial support and information to patients could lead to a better acceptance of reduced follow-up. The MaCare trial combines a reduced follow-up strategy with additional psychosocial support. Less frequent follow-up can reduce the burden on medical specialists and costs. The educational group programme can improve QoL of patients, but also less frequent follow-up can improve QoL by reducing the anxiety experienced for each follow-up visit. Results of the trial will provide knowledge on both costs and psychosocial aspects regarding follow-up and are expected in 2009.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design of the MaCare trial 'Improving the quality and efficiency of follow-up after curative treatment for breast cancer'. F-up = follow-up; R = randomisation; EGP = educational group programme; BCN = breast care nurse; NP = nurse practitioner; N = number of patients

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
    1. Rutgers EJ, van Slooten EA, Kluck HM. Follow-up after treatment of primary breast cancer. Br J Surg. 1989;76:187–190. - PubMed
    1. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, Palli D, del Roselli TM, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005:CD001768. - PubMed
    1. Brada M. Is there a need to follow-up cancer patients? Eur J Cancer. 1995;31A:655–657. doi: 10.1016/0959-8049(95)00079-X. - DOI - PubMed
    1. Dewar JA, Kerr GR. Value of routine follow up of women treated for early carcinoma of the breast. Br Med J (Clin Res Ed) 1985;291:1464–1467. - PMC - PubMed

Publication types